PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology

PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology

Cancer patients treated with immune checkpoint inhibitors (ICIs) are exposed to a high risk of atherosclerosis and cardiometabolic diseases due to systemic inflammatory conditions and immune-related atheroma destabilization. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key protein invo...

Full description

Bibliographic Details
Main Authors: Vincenzo Quagliariello, Irma Bisceglia, Massimiliano Berretta, Martina Iovine, Maria Laura Canale, Carlo Maurea, Vienna Giordano, Andrea Paccone, Alessandro Inno, Nicola Maurea
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Cancers
Subjects:
cardio-oncology
cardioprotection
cancer
immune-checkpoint inhibitors
atherosclerosis
cholesterol
Online Access:https://www.mdpi.com/2072-6694/15/5/1397

Internet

https://www.mdpi.com/2072-6694/15/5/1397

Similar Items